Medications for Astrocytoma

6 results

  • Everolimus (everolimus)

    (Everolimus)
    Mylan Pharmaceuticals Inc.
    Usage: Everolimus is indicated for the treatment of Tuberous Sclerosis Complex (TSC) in patients aged 1 year and older for SEGA requiring intervention that cannot be curatively resected, and as adjunctive therapy for TSC-associated partial-onset seizures in patients aged 2 years and older.

  • Everolimus (everolimus)

    (Everolimus)
    Natco Pharma Limited
    Usage: Everolimus is indicated for postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer, and for adult patients with progressive neuroendocrine tumors, renal cell carcinoma post sunitinib/sorafenib failure, renal angiomyolipoma in tuberous sclerosis, and subependymal giant cell astrocytoma in TSC.

  • Temozolomide (temozolomide)

    (TEMOZOLOMIDE)
    Camber Pharmaceuticals, Inc.
    Usage: Temozolomide capsules are indicated for treating adults with newly diagnosed glioblastoma (alongside radiotherapy and as maintenance) and for both adjuvant and refractory treatment of newly diagnosed anaplastic astrocytoma.

  • Temozolomide (temozolomide)

    (Temozolomide)
    Lannett Company, Inc.
    Usage: Temozolomide is indicated for adult patients with newly diagnosed glioblastoma multiforme, used alongside radiotherapy and as maintenance treatment. It is also indicated for those with refractory anaplastic astrocytoma who have disease progression following treatment with nitrosourea and procarbazine.

  • Temozolomide (temozolomide)

    (temozolomide)
    Rising Pharma Holdings, Inc.
    Usage: Temozolomide capsules are indicated for adults with newly diagnosed glioblastoma (in combination with radiotherapy and maintenance) and for the adjuvant and treatment of refractory anaplastic astrocytoma.

  • Voranigo

    (vorasidenib)
    Servier Pharmaceuticals LLC
    Usage: VORANIGO is indicated for treating adult and pediatric patients aged 12 and older with Grade 2 astrocytoma or oligodendroglioma that harbor IDH1 or IDH2 mutations, following surgical interventions such as biopsy or resection.